Article
Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsy
2020-09-11
Abstract excerpt
The clinical spectrum associated with SCN2A de novo mutations (DNMs) continues to expand and includes autism spectrum disorder with or without seizures, in addition to early and late seizure onset developmental and epileptic encephalopathies (DEEs). Recent biophysical studies on SCN2A variants suggest that the majority of early seizure onset DEE DNMs cause gain of function. Gain of function in SCN2A, the principa...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 92bf5397-920b-5102-96d2-6c0142e03ced
- DOI
- 10.1101/2020.09.09.289900
